Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), ENPP3 inhibitors(Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 17 Apr 2023 |






